(Reuters) – French biotech firm Valneva said on Wednesday that preliminary studies showed that three doses of its inactivated COVID-19 vaccine candidate neutralised the Omicron variant of the disease.
(Reporting by Sarah Morland; Editing by Hugh Lawson)
